Gland Pharma Share Price Target From 2024 to 2030: Gland Pharma is one of the leading pharmaceutical companies in India, focusing on producing injectable formulations that cover almost all therapeutic areas. During the last two to three years, Gland has emerged as one of the major contract manufacturing companies serving global clients while expanding its footprint in regulated markets. This business stands poised for growth as equipped well in robust manufacturing capabilities while following the high quality and the best standards. Its making it a very beautiful investment opportunity. It follows analysis on Gland Pharma share price target between years 2024 to 2030 and gives a description related to its performance metrics along with the ownership structure so growth prospects.
Company Overview
Gland Pharma, established in 1978, is headquartered in Hyderabad, India. This company has become one of the leading generic injectable manufacturers in the country. The company is present all over the world and has always been quality-oriented to ensure it has regulatory approvals from the U.S. FDA among others. It can be determined that Gland Pharma’s strength in market position is driven through strategic R&D and injectable manufacturing for various therapeutic segments, like oncology, cardiology, and pain management.
With a history of successful partner agreements and contracts in manufacture, Gland Pharma established itself as one of the trusted suppliers to these global pharma giants. The key growth driver would be based on the demand for affordable but quality injectable solutions, specially in regulated markets that yield a higher margin than domestic market sales and a lesser rate of price wars.
Gland Pharma Share Price Details
- Latest Open: ₹1,601.00
- 52-Week High: ₹2,220.95
- 52-Week Low: ₹1,509.30
- Current Market Price: ₹1,822.00
- Market Cap: ₹30,190 Crores
- P/E Ratio: 41.57
- Dividend Yield: 1.10%
Talking about the last one year, Gland Pharma shares have appreciated well as it has risen by approximately 15.69%. The valuation parameters for this company are moderately strong where the P/E ratio is at 41.57. In fact, it has been observed that the present valuation value depicts the tremendous growth opportunity in the injectable drug segment for Gland Pharma as it expands the diversity of its product lines and expands its geographical footprint.
Shareholding Pattern and Institutional Investors For Gland Pharma Share Price
Ownership structure is reflective of a high promoter as well as institutional holding of Gland Pharma:
- Promoters: 51.83% (no change in the Sept 2024 quarter
- Mutual Funds: 32.83% (rose from 30.53% in the preceding quarter
- Retail Investors and others: 8.32%
- FIIs: 4.47% (-6.88% of the previous quarter
- Others Domestic Institutions: 2.54%
Now the mutual funds have increased it to 32.83% at the end of September quarter of 2024 from 30.53%. It appears that even the domestic institutional investors, who had lost confidence from the company, are gathering confidence again. The amount of FII has fallen from 6.88% to 4.47% and the investors have reduced from 184 to 175, mainly because foreign investors are making a change in their strategy or following the market directions. The promoters hold maximum portion of 51.83%, which reflects longterm confidence in the growth potentials of the company.
Projected Gland Pharma Share Price Targets for 2024 to 2030
Considering that Gland Pharma has an already established presence, a great focus on R&D and expansion into high-growth markets, here is how the projected share price might look for Gland Pharma from 2024 to 2030.
| YEAR | SHARE PRICE TARGET |
| 2024 | ₹2300 |
| 2025 | ₹2560 |
| 2026 | ₹2825 |
| 2027 | ₹3145 |
| 2028 | ₹3456 |
| 2029 | ₹3785 |
| 2030 | ₹4020 |
2024 – Projected Gland Pharma Share Price Target: ₹2,300
Strong injectable formulation focus and entering the regulated market will drive the growth of Gland Pharma. Continuous new product launches as well as strategic partnership with this global pharmaceutical company will boost revenue and profitability for Gland Pharma.
Projected Gland Pharma Share Price Target in 2025: ₹2,560
By 2025, the stock of Gland Pharma is expected to reach ₹2,560. Its growth will be driven by entering new therapeutic segments and expanding market share. Increased demand for injectables, which is expected to rise post the pandemic, coupled with quality commitment by Gland Pharma, will make it reap a strong pipeline of product approvals.
2026 – Projected Gland Pharma Share Price Target: ₹2,825
In 2026, share price target is expected from Gland Pharma at ₹2,825. The company will yield profitability due to expansion into emerging markets and investment into high margin products such as complex injectables. Secondly, a niche focus area of oncology and biosimilars by Gland Pharma is in tandem with overall industry trends and shall enable higher market share capturing.
Projected Gland Pharma Share Price Target for the year 2027 ₹3,145
The share price of Gland Pharma will reach ₹3,145 by 2027 with the advancement of R&D and diversification of its portfolio. Revenue growth will continue to emanate from its improved production capabilities and expansion into new regulated markets. In the future, the contract manufacturing arrangement with pharmaceutical companies in complex and specialty injectables will also add to the positive growth.
Projected Gland Pharma Share Price Target: ₹3,456 by 2028
It shall reach ₹3,456 by 2028, as the company is very likely to gain investor confidence through continued research in high demand product development and production using sustainable practices. International customers are likely to grow together with strategic investments in the newer manufacturing facilities.
Gland Pharma Share Price Target for 2029 : ₹3,785
The forecast future target share price of the year 2029 by Gland Pharma will be at ₹3,785. Further expansion in the newer geographical areas and even a higher penetration into its currently existing markets would lead the company to build a great increase in its revenue. It remains focused on investments regarding the R&D and on even maintaining higher quality standards while keeping up with intent regarding this sector, providing numerous opportunities for Gland Pharma across the world in future.
Targeted Gland Pharma Share Price Value by 2030 -₹4,020
By 2030, Gland Pharma share price will be at the level of about ₹4,020. Growth coming from the firm will come on sustainable demand in injectable pharmaceuticals along with orientation towards innovation and operational efficiencies. With Gland Pharma strengthening its market presence further with expansion into biologics and biosimilars, long-term growth outlooks look promising.
Growth Drivers For Gland Pharma Share Price
- Increasing Demand for Injectable Pharmaceuticals: The injectable market continues to grow as vaccines, biologics, and specialty drugs gain increasing demand on which Gland Pharma also leads.
- Business in the Regulated Markets: Sustained profitability is assured from businesses in regulated markets like U.S. and Europe for Gland Pharma.
- Strategic Partnerships: It has strategic partnership ties with global pharmaceutical players which enhance its product offerings in terms of increasing market share.
- Investment in R&D on Complex Injectables: High-value products such as oncology and biosimilars form the core segment where Gland Pharma is apt for growth in specialized therapy areas.
- Focus on Quality and Compliance: Gland Pharma follows a strict quality aspect as the regulatory requirements provide the best competitive advantage, but potential risks are its own weak points. High degree of regulatory requirements to run a business in regulated markets, proving to be expensive for the organization in terms of efficiency of operations.
- Pharmaceuticals: It’s an extremely competitive industry mainly because of the key players of the market, especially the big guns like Sanofi, GSK, and so forth. Emerging entrants might disturb the market share. Gland Pharma will suffer from dependency on contract manufacturing wherein almost all revenues depend on contracts.
- Economic and Currency Risks: Gland Pharma is conducting businesses in different international markets and hence is exposed to currency fluctuations and economic instability.
Gland Pharma Share Price Target FAQs
1. What is the Gland Pharma share price prediction for 2030?
By 2030, the Gland Pharma share price target will be around ₹4,020, considering the expected growth in regulated markets, diversified products, and growing injectable demand.
2. What are the growth drivers for Gland Pharma?
Gland Pharma is growing on the back of injectable drugs demand, regulated market entry, strategic collaboration, and investment in complex and specialty injectables. Quality standards also support its market position.
3. Why is FII holding down for Gland Pharma?
FII holding has declined from 6.88% to 4.47% in the quarter ending September 2024, which might be due to profit booking and rebalancing by the foreign investors. Nevertheless, this cannot weaken the tremendous attraction of the company among the mutual funds.
4. Mutual fund holding in Gland Pharma has altered in which way?
Mutual fund holding has surged from 30.53% to 32.83% in the quarter ending September 2024, which reflects tremendous confidence among the domestic institutional investors.
5. What are the significant risks in investing in Gland Pharma?
Regulatory compliance issues, competitive pressures, dependence on contract manufacturing, and exposure to economic and currency fluctuations are some of the key risks. The company’s high dependence on regulated markets may lead to operational disruptions if regulatory hurdles arise.
6. How does Gland Pharma’s focus on R&D contribute to its growth?
Investments in Gland Pharma in R&D, such as complex injectables, biosimilars, and oncology drugs, enhance the product portfolio and strengthen the position within the high-growth therapeutic areas that support long-term revenue growth.
